The University of Oxford is a collegiate research university in Oxford, England. There is evidence of teaching as early as 1096, making it the oldest university in the English-speaking world and the world's second-oldest university in continuous operation.

During the past decade, University of Oxford conducted 62 clinical trials. In the 10-year time frame, 62 clinical trials started and 6 clinical trials were completed, i.e. on average, 9.7% percent of trials that started reached the finish line to date. In the past 5 years, 28 clinical trials started and 6 clinical trials were completed. i.e. 21.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Oxford" #1 sponsor was "University of Oxford" with 49 trials, followed by "NuCana plc" with 2 trials sponsored, "Royal Devon and Exeter NHS Foundation Trust" with 2 trials sponsored, "UMC Utrecht" with 2 trials sponsored and "Abide Therapeutics" with 2 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Oxford" #1 collaborator was "University of Oxford" with 10 trials as a collaborator, "Oxford University Hospitals NHS Trust" with 6 trials as a collaborator, "Janssen Research & Development, LLC" with 3 trials as a collaborator, "King's College London" with 3 trials as a collaborator and "Medical Research Council" with 3 trials as a collaborator. Other collaborators include 99 different institutions and companies that were collaborators in the rest 97 trials.

According to Clinical.Site data, the most researched conditions in "University of Oxford" are "Depression" (7 trials), "Cognition" (5 trials), "Depressive Disorder" (5 trials), "Antidepressive Agents" (4 trials) and "COVID-19" (3 trials). Many other conditions were trialed in "University of Oxford" in a lesser frequency.

Most popular intervention types in "University of Oxford" are "Drug" (34 trials), "Other" (18 trials), "Behavioral" (10 trials), "Biological" (7 trials) and "Device" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Citalopram" (3 trials), "Magnetic Resonance Imaging" (2 trials), "PF-04995274" (2 trials) and "Placebo Oral Tablet" (2 trials). Other intervention names were less common.

The vast majority of trials in "University of Oxford" are 79 trials for "All" genders, 4 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "University of Oxford". 1 are not yet recruiting, 11 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 48 completed trials in University of Oxford, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in University of Oxford, 14 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 29 trials that are defined as “Not Applicable".

University of Oxford has several departments that took part in Clinical trials: "Department of Psychiatry, University of Oxford" - 17 trials, "Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital" - 8 trials, "Oxford Centre for Diabetes, Endocrinology and Metabolism" - 6 trials, "Oxford Respiratory Trials Unit" - 4 trials, "Oxford Centre for Clinical Magnetic Resonance Research (OCMR)" - 4 trials, "Cardiovascular Clinical Research Facility, Dept of Cardiovascular Medicine, University of Oxford" - 4 trials, "Hepatology Clinical Trial Unit, John Radcliffe Hospital" - 3 trials, "Clinical Research Unit, OCDEM, Churchill Hospital" - 3 trials, "Wellcome Centre for Integrative Neuroimaging (WIN)" - 3 trials, "ICRF Medical Oncology Unit" - 2 trials, "Myanmar Oxford Clinical Research Unit" - 2 trials, "Critical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford" - 2 trials